Literature DB >> 7928366

Analysis of the effectiveness of emergency countermeasures in the 30-km zone during the early phase of the Chernobyl accident.

I A Likhtarev1, V V Chumack, V S Repin.   

Abstract

Some radiation-emergency countermeasures, including evacuation, were implemented in the settlements of the 30-km zone during the early phase of the accident at the Chernobyl Nuclear Power Plant. These countermeasures are described and compared with the international recommendations. An analysis of the effectiveness of the emergency countermeasures was conducted based upon the results of a wide-scale public survey. Quantitative assessments of the effectiveness (dose reduction) of the countermeasures were derived.

Mesh:

Year:  1994        PMID: 7928366     DOI: 10.1097/00004032-199411000-00010

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  3 in total

1.  American Thyroid Association Scientific Statement on the Use of Potassium Iodide Ingestion in a Nuclear Emergency.

Authors:  Angela M Leung; Andrew J Bauer; Salvatore Benvenga; Alina V Brenner; James V Hennessey; James R Hurley; Stacey A Milan; Arthur B Schneider; Krishnamurthi Sundaram; Daniel J Toft
Journal:  Thyroid       Date:  2017-06-21       Impact factor: 6.568

2.  Limited internal radiation exposure associated with resettlements to a radiation-contaminated homeland after the Fukushima Daiichi nuclear disaster.

Authors:  Masaharu Tsubokura; Shigeaki Kato; Masahiko Nihei; Yu Sakuma; Tomoyuki Furutani; Keisuke Uehara; Amina Sugimoto; Shuhei Nomura; Ryugo Hayano; Masahiro Kami; Hajime Watanobe; Yukou Endo
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

3.  Comparative analysis of the countermeasures taken to mitigate exposure of the public to radioiodine following the Chernobyl and Fukushima accidents: lessons from both accidents.

Authors:  Vladimir Uyba; Alexander Samoylov; Sergey Shinkarev
Journal:  J Radiat Res       Date:  2018-04-01       Impact factor: 2.724

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.